Physician profile
Serag Dredar
NPI 1922217637
$3,819.74
in general payments reported to CMS, 2019-2025
16 companies · $752 in 2025
The $752 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $121 · 2021: $87.41 · 2022: $1,093 · 2023: $581 · 2024: $639 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,971.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,018.52 | 2019-2023 | Resolution 360 Clip |
| Genzyme Corporation | $638.30 | 2022-2025 | |
| Abbvie INC. | $620.10 | 2019-2025 | |
| Gilead Sciences, INC. | $323.71 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $299.20 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $276.57 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.49 | 2023-2025 | Xifaxan, Plenvu |
| Janssen Scientific Affairs, LLC | $138.67 | 2025 | |
| Madrigal Pharmaceuticals | $130.59 | 2024 | Resmetirom |
| 3-D Matrix, INC. | $77.89 | 2024 | |
| Olympus America INC. | $38.45 | 2023-2024 | Endoclot Sis, Evis Exera III Colonovideoscope, Gastrointestinal Videoscope |
| Regeneron Healthcare Solutions, INC. | $31.89 | 2024-2025 | Dupixent |
| Exact Sciences Corporation | $23.92 | 2023 | Cologuard Collection Kit |
| Erbe USA INC | $23.69 | 2023 | Erbe Hybrid Knife |
| Pfizer INC. | $19.95 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apollo Endosurgery US INC | $16.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serag Dredar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.